Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs, Inc. (KNW) is a pioneering company in the medical diagnostics sector, dedicated to the development, marketing, and sales of cutting-edge technologies. The company specializes in utilizing electromagnetic energy to identify, authenticate, and analyze various substances and materials through its proprietary Bio-RFID and ChromaID technologies.
The Bio-RFID technology is revolutionizing the industry by enabling non-invasive glucose monitoring, providing a significant advancement for diabetes management. Similarly, the ChromaID technology uses structured light to capture unique spectral patterns known as ChromAIDs, which can be matched against databases to identify and detect markers invisible to the human eye. These technologies offer potential solutions that were previously only possible with large, lab-based tests.
Know Labs is currently focused on the development of a wearable device designed to measure blood glucose levels without the need for fingersticks or microneedles. This innovative product aims to improve the quality of life for individuals with diabetes by providing a painless and convenient method of monitoring blood sugar levels.
The company has recently achieved significant milestones in its research and development efforts, showcasing its commitment to pushing the boundaries of medical diagnostics. Know Labs is also actively engaged in forging strategic partnerships to enhance its technological capabilities and expand its market reach.
Financially, Know Labs continues to invest in research and development, ensuring it remains at the forefront of medical diagnostic innovation. The company's disruptive technologies hold the promise of making advanced diagnostics more accessible and affordable, thereby transforming the landscape of healthcare.
For the latest updates, news, and developments related to Know Labs, Inc., visit our news section or follow us on our social media channels.
Know Labs, Inc. (KNW) has announced successful results from a proof-of-principle study demonstrating the accuracy of its proprietary Bio-RFID technology in non-invasive medical diagnostics. Conducted in collaboration with Mayo Clinic, the study, titled "Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions," showcased a remarkable 100% accuracy rate in measuring various analytes in vitro. This breakthrough technology captures molecular signatures using radio waves, with glucose monitoring being its first application. Market trends highlighting the need for affordable, accurate non-invasive healthcare solutions further bolster the significance of these results. The full study awaits peer-review publication.
Know Labs, Inc. (NYSE American: KNW) has formed a new Scientific Advisory Board (SAB) featuring leading experts in medical technology and human health. This board aims to enhance Know Labs' efforts in algorithm refinement, device development, and clinical trial design for its Bio-RFID technology, which aims to offer non-invasive glucose monitoring. The SAB includes esteemed members like Dr. Benjamin Smarr and Dr. Mark Aloia, who bring extensive backgrounds in research and technology. Know Labs emphasizes 2023 as a year of prioritizing external validation of its non-invasive diagnostic technology.
Know Labs, Inc. (NYSE American: KNW) reported its financial results for Q1 2023, revealing a net loss of $3.82 million, a decrease from a $5.36 million loss in Q1 2022. This translates to a loss per share of $0.08, compared to $0.15 the previous year. Research and development expenses surged to $1.74 million from $886,000, attributed to staffing and Bio-RFID technology development aimed at FDA trials. Cash and equivalents decreased to $9.68 million from $12.59 million. The company estimates it has sufficient cash to fund operations until February 14, 2024. Shareholder equity fell to $7.1 million from $9.9 million in the prior quarter.
Know Labs, Inc. (AMEX: KNW) is set to hold a webcast on February 14, 2023, at 1:30 PM PT, to discuss business updates and results from Q1 FY 2023, which ended on December 31, 2022. The webcast will be accessible live and for replay at knowlabs.co/investors. The company specializes in non-invasive medical diagnostic technology, utilizing its Bio-RFID™ technology to develop wearable and mobile diagnostics. Its first product is a non-invasive glucose monitor awaiting FDA clearance. Investors are encouraged to submit questions during the webcast for further insights.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
What does Know Labs, Inc. specialize in?
What is Bio-RFID technology?
What is ChromaID technology?
What is the latest product being developed by Know Labs?
What are ChromAIDs?
How does Know Labs' technology differ from traditional diagnostic methods?
What are the recent achievements of Know Labs?
How does Know Labs contribute to diabetes management?
Who can benefit from Know Labs' technologies?
Where can I find the latest news about Know Labs, Inc.?
